Towards the lean lab: the industry challenge.

In anatomic pathology, the current state encompassing the pre-analytic processes of tissue collection, handling, examination, preparation, processing, and storage are largely uncontrolled, inconsistently performed, and/or not standardized according to the sound scientific data. Pre-analytic defects result in nearly three-quarters of the problems in laboratory diagnostics. This is evident in quality surveys from well-respected institutions that document high miss rates in the required basics of information related to patient and tissue identity, let alone parameters documenting quality aspects related to the surgical specimen and its preservation. This talk will describe the historical approach to tissue processing and identify gaps from worldwide observations in current laboratory practices. It will also offer potential methodological and technological solutions and process improvements that laboratories may consider in serving the ultimate users of pathology information: the clinician and the patient. It illustrates the need for scientifically validated specimen guidelines and a performance based, standardized and documented "chain of custody" of the pre-analytical steps from the patient's body through fixation. For thought leaders and professional standard setters, opportunities for optimizing molecular studies exist in specimen collection, transfer, grossing, fixation, and decalcification protocols. In this evolving era of molecular profiling and personalized therapeutic decision-making, a well-reasoned and coordinated focus on pre-analytic processes that optimizes specimens for subsequent testing will result in: Improved specimen quality for molecular testing Improved accuracy of diagnostic and molecular test results Reduced Turnaroundtimes for same-day diagnosis Enhanced satisfaction of clinicians and patients.

[1]  P. Hogendoorn,et al.  Molecular pathology of sarcomas: concepts and clinical implications , 2009, Virchows Archiv.

[2]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Wesseling,et al.  Molecular Diagnostics as a Tool to Personalize Treatment in Adult Glioma Patients , 2006, Technology in cancer research & treatment.

[4]  C. Fletcher,et al.  Molecular prognostication for soft tissue sarcomas: are we ready yet? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Bonin,et al.  Effects of Formalin, Methacarn, and FineFIX Fixatives on RNA Preservation , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[6]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[7]  Michael Krauthammer,et al.  PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.

[8]  P. Kaposi-Novák,et al.  Effect of Formalin, Acetone, and RNAlater Fixatives on Tissue Preservation and Different Size Amplicons by Real-Time PCR from Paraffin-Embedded Tissue , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  M. Monden,et al.  Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. , 1999, Nucleic acids research.

[10]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Klebs Die Einschmelzungs-Methode, ein Beitrag zur mikroskopischen Technik , 1869 .

[12]  W. Böcker [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. , 2002, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[13]  Claudio Montero,et al.  The Antigen-Antibody Reaction in Immunohistochemistry , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  D. Dabbs Immunohistochemical protocols: back to the future. , 2008, American journal of clinical pathology.

[15]  M. Hayat Microscopy, Immunohistochemistry, and Antigen Retrieval Methods: For Light and Electron Microscopy , 2002 .

[16]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[17]  T. Ruers,et al.  Cost effectiveness of a new strategy to identify HNPCC patients , 2004, Gut.

[18]  Bernd W Scheithauer,et al.  Development of the WHO Classification of Tumors of the Central Nervous System: A Historical Perspective , 2009, Brain pathology.

[19]  C. Oliver,et al.  Fixation and embedding. , 1999, Methods in molecular biology.

[20]  N. Goldstein,et al.  Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. , 2003, American journal of clinical pathology.

[21]  K. Flaherty,et al.  Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. , 2009, Cancer research.

[22]  A. Leong,et al.  The Effects of Progressive Formaldehyde Fixation on the Preservation of Tissue Antigens , 1989, Pathology.

[23]  C. Fletcher The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.

[24]  J. M. Wilkinson,et al.  Evaluation of Ethanol-based Fixatives as a Substitute for Formalin in Diagnostic Clinical Laboratories , 2000 .

[25]  A. Sapino,et al.  Critical steps in tissue processing in histopathology. , 2012, Recent patents on DNA & gene sequences.

[26]  R. Dapson Fixation for the 1990's: a review of needs and accomplishments. , 1993, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[27]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. O'Leary,et al.  Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  P. Wesseling,et al.  MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas , 2007, Laboratory Investigation.

[30]  J. Meyerhardt,et al.  KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 , 2009, Clinical Cancer Research.

[31]  V. Nosé,et al.  Endocrine Tumors as Part of Inherited Tumor Syndromes , 2011, Advances in anatomic pathology.

[32]  H. Rugo,et al.  The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations , 2007, Current treatment options in oncology.

[33]  P. Wesseling,et al.  Preparing pathology for personalized medicine: possibilities for improvement of the pre‐analytical phase , 2011, Histopathology.

[34]  Richard D Kolodner,et al.  Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. , 2009, Cancer research.

[35]  A. Iafrate,et al.  Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers , 2008, Journal of neuropathology and experimental neurology.

[36]  William E. Grizzle,et al.  Introduction to the Theory and Practice of Fixation of Tissues , 2001 .

[37]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[38]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[39]  Gianni Bussolati,et al.  Tissue transfer to pathology labs: under vacuum is the safe alternative to formalin , 2008, Virchows Archiv.

[40]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  J. Lasota,et al.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.

[42]  A. Sapino,et al.  Formalin Fixation at Low Temperature Better Preserves Nucleic Acid Integrity , 2011, PloS one.

[43]  M. Ligtenberg,et al.  Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting , 2008, The American journal of surgical pathology.